Sugi Predict

Sugi Predict / Compounds / SCHEMBL535527

SCHEMBL535527

SCHEMBL535527

[CH2]Oc1ccc(C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ KIF11 P52732 6/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAOB P27338 4/20 0.42
▸ IDO1 P14902 2/20 0.41
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ ORAI1 Q96D31 1/20 0.41
▸ ORAI2 Q96SN7 1/20 0.41
▸ ORAI3 Q9BRQ5 1/20 0.41
▸ TRPV6 Q9H1D0 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ AOC3 Q16853 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11148692 0.78 CA1 (0.52) CA1CA2CA9KIF11ALDH1A1
SCHEMBL1685383 0.78 CA1 (0.52) CA1CA2CA9KIF11ALDH1A1
SCHEMBL63468 0.76 ALDH1A1 (0.67) KIF11ALDH1A1TSHRIDO1CES2
SCHEMBL92001 0.76 CA1 (0.50) CA1CA2CA9KIF11ALDH1A1
SCHEMBL29377645 0.76 LTA4H (0.50) CA1CA2CA9KIF11ALDH1A1
SCHEMBL11452215 0.74 TSHR (0.43) TSHR
SCHEMBL3753468 0.74 IDO1 (0.41) IDO1CES2
SCHEMBL22015095 0.74 CA1 (0.48) CA1CA2CA9KIF11ALDH1A1
SCHEMBL514499 0.74 MAPT (0.47) KIF11ALDH1A1TSHRMAOBAOC3
SCHEMBL255255 0.74 CA1 (0.58) CA1CA2CA9MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2010-11-18 — — US claimed
US-20090239909-A1 TREATMENT OF METABOLIC SYNDROME WITH LACTAMS AMPLA PHARMACEUTICALS INC. (US) 2009-09-24 — — US claimed
WO-2009073138-A2 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES AMPLA PHARMACEUTICALS INC. (US) 2009-06-11 — — WO claimed
CN-1317277-C Benzofuran derivatives and their use as pharmaceutical preparations ARPIDA AG (CH) 2007-05-23 — — CN claimed
US-7030130-B2 Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2006-04-18 — — US claimed
EP-1307445-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2005-12-21 — — EP claimed
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents EVOLVA SA (CH) 2004-02-19 — — US claimed
CN-1440404-A Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2003-09-03 — — CN claimed
EP-1307445-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Arpida AG, (CH) 2003-05-07 — — EP claimed
WO-2002010157-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 — — WO claimed
US-4562204-A ANTITUMOR, ANTILEUKEMIA AGENT ONO PHARMACEUTICAL CO., LTD. (JP) 1985-12-31 — — US claimed
EP-0099672-A2 Trans-Delta 2-prostaglandin D derivatives, process for their preparation and compositions containing them ONO PHARMACEUTICAL CO., LTD. (JP) 1984-02-01 — — EP claimed
EP-0097023-A2 Prostaglandin D derivatives, process for their preparation and compositions containing them ONO PHARMACEUTICAL CO., LTD. (JP) 1983-12-28 — — EP claimed
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2024-06-06 — — US disclosed
US-20230117695-A1 ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-04-20 — — US disclosed
US-11492352-B2 Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2022-11-08 — — US disclosed
EP-0011370-A1 Process for preparing 2-chlorosulfinyl-azetidinones ELI LILLY AND COMPANY (US) 1980-05-28 — — EP disclosed
US-4159272-A Process for 2-chlorosulfinylazetidin-4-ones ELI LILLY AND COMPANY (US) 1979-06-26 — — US disclosed
US-4113863-A PROSTENOIC ACID DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1978-09-12 — — US disclosed
US-4086362-A Prostenoic acid derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1978-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11492352-B2 Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative LUC7L2, CXCR6, RRP12 CA1 797/4885CA2 1027/4885CA9 1134/4885
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 CA1 1892/4885CA2 1644/4885CA9 1627/4885
US-20090239909-A1 TREATMENT OF METABOLIC SYNDROME WITH LACTAMS PCSK9, COASY, CPT1B CA1 4668/4885CA2 3276/4885CA9 2407/4885
US-20230117695-A1 ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE CDK7, CCNA1, CCR10 CA1 1379/4885CA2 1543/4885CA9 1638/4885
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents SBDS, BPTF, DCXR CA1 4871/4885CA2 4608/4885CA9 4582/4885
US-20100292289-A1 TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES GPR119, CPT1A, GLS2 CA1 4705/4885CA2 3586/4885CA9 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.